| 0.77 -0.02 (-2.53%) | 12-08 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.29 | 1-year : | 1.86 |
| Resists | First : | 1.1 | Second : | 1.6 |
| Pivot price | 0.68  |
|||
| Supports | First : | 0.31 | Second : | 0.25 |
| MAs | MA(5) : | 0.73 |
MA(20) : | 0.59 |
| MA(100) : | 1.1 |
MA(250) : | 0.81 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.7 |
D(3) : | 32.3 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 9.48 | Low : | 0.07 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BGLC ] has closed below upper band by 40.4%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.85 - 0.85 | 0.85 - 0.85 |
| Low: | 0.74 - 0.75 | 0.75 - 0.75 |
| Close: | 0.76 - 0.77 | 0.77 - 0.78 |
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Mon, 27 Nov 2023
US Stocks Lower; Dow Falls Over 50 Points - BioNexus Gene Lab (NASDAQ:BGLC), Biodexa Pharmaceuticals (NAS - Benzinga
Fri, 24 Nov 2023
US Stocks Mixed; Dow Gains 50 Points - BioNexus Gene Lab (NASDAQ:BGLC), Amazon.com (NASDAQ:AMZN) - Benzinga
Mon, 20 Nov 2023
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Mon, 16 Oct 2023
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director - Marketscreener.com
Wed, 23 Aug 2023
Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today? - InvestorPlace
Wed, 16 Aug 2023
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 18 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 58.8 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 24 (K) |
| Shares Short P.Month | 23 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.54 |
| Profit Margin | -30 % |
| Operating Margin | -99 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.58 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -2.86 |
| PEG Ratio | 0 |
| Price to Book value | 1.42 |
| Price to Sales | 1.31 |
| Price to Cash Flow | -23.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|